Bluebird Reports Early Results From Upgraded Gene Therapy – Xconomy
Xconomy |
Bluebird Reports Early Results From Upgraded Gene Therapy
Xconomy One of the year's most closely watched clinical studies could lead to a landmark approval of a gene therapy and throw wide open the debate over how to pay for expensive drugs. The first drips of data have emerged. Bluebird Bio (NASDAQ: BLUE) says the … Bluebird Bio's gene therapy for blood disorders yields some … Early Data for bluebird bio Gene–Therapy Candidate Show Some Promise Bluebird Bio rebuilds case for blood disorder gene therapy |
